Magic Mushrooms Could Game-Changer for Depression
Magic mushrooms may be the biggest advance in treating depression since Prozac,” says Newsweek.
Not only has the US FDA granted “breakthrough status” to psilocybin, dozens of medical studies are seeing positive study results, including Johns Hopkins Medicine and New York University. In addition, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR. Even The Beckley Foundation has said, “Psilocybin was well-tolerated and induced rapid and lasting reduction in the severity of depressive symptoms.”
Better, with plenty of clinical trials supporting psilocybin treatments, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate the drug into their own drug pipelines. All could be substantial catalysts for companies, such as Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), Mind Medicine (NASDAQ:MNMD) (NEO:MMED), Cybin Inc. (NEO:CYBN)(NYSE:CYBN), Field Trip Health Ltd. (NASDAQ:FTRP)(TSX:FTRP), and COMPASS Pathways (NASDAQ:CMPS).
